Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator of RNA polymerase II transcription subunit 22 (MED22) is a core component of the Mediator complex, a large multiprotein coactivator essential for the regulated transcription of most RNA polymerase II-dependent genes[1][4][6]. MED22 is structurally part of the 'head' module of the Mediator and forms a heterodimer with MED11, creating a conserved four-helix bundle that is critical for the assembly and stability of the pre-initiation complex (PIC) on gene promoters, including recruitment of basic transcriptional machinery and interaction with TFIIH[2]. MED22 plays a specialized and essential role in podocyte homeostasis; its loss leads to podocyte cellular degeneration, vacuole formation, and progressive renal failure in mouse models[1]. While MED22 has not been demonstrated as a direct drug target, it is implicated in kidney disorders such as glomerulopathies and may be a candidate for further disease research. It is not an enzyme, receptor, transporter, or ion channel, but a transcriptional regulator as part of the Mediator complex[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator of RNA polymerase II transcription subunit 22 (MED22).